EPIC, CareRef, and More: Optimizing Clinical Decision Support Tools

February 8, 2024

Minnesota Center of Excellence in Newcomer Health



Acknowledgment

The Minnesota Center for Excellence in Newcomer Health is supported by 1 NU50CK000563 from the U.S. Centers for Disease Control and Prevention.

The Minnesota Medical Association facilitated the CMEs.

No financial conflicts of interest.















Learning Objectives

- Identify existing electronic clinical decision tools and available learning opportunities for newcomer health
- Employ clinical decision tools to perform appropriate screening and management actions for newly arrived newcomer patients
- Utilize newcomer health clinical decision tools to identify patients in need of outreach for completion of newcomer screening and management
- Understand how existing newcomer clinical decision support tools can be adapted to support broader populations



Today's Speakers



Jeremy Michel, MD
Children's Hospital of
Philadelphia



Kailey Urban, MPH

Minnesota Department of

Health



Sarah Kuech, RN MSc MCHES

Minnesota Center of

Excellence

(Moderator)



Agenda

- Overview of Clinical Decision Tools
- Demonstration of CareRef and VaxRef
- Demonstration of Decision Support Tools
- Applying these tools to broader uses and populations
- Additional learning opportunities
- Q&A
- Wrap Up



Newcomer Health Clinical Decision Support



Refugee Health Decision Support

Publicly available Clinical Decision Support for Newcomer Health (Revised: May 2023)

Refugee Health Decision Support (https://cds.ahrq.gov/cdsconnect/artifact/refugee-health-decision-support)



Clinical Decision Support for Newcomer Health

- Is Clinical Decision Support right for Newcomer Health
 - Arrival testing is complex and depends on multiple variables
 - Follow up testing and management for particular age groups and underlying health conditions
 - Complex visit considerations including language and cultural barriers to care
 - Outside data needs to be considered for care decisions
 - Care recommendations apply routinely across the United States



Clinical Decision Support

A clinical decision support (CDS) system is intended to improve healthcare delivery by enhancing medical decisions with targeted clinical knowledge, patient information, and other health information.

(Osheroff, 2012)

Clinical Decision Support Modalities

- Alerts
- Reminders
- Computerized Provider Order Entry (CPOE)
- Documentation Templates

- "Linked in" Information
- Patient Instructions
- Handouts
- Diagnostic Support
- Order Sets




Good Clinical Decision Support: The 5 Rights

- Applying the "5 Rights" to newcomer health clinical decision support
 - Right information
 - How do we know if a patient in need of newcomer health
 - What data is relevant to help make decisions
 - Right person
 - Who on the team needs to see which information? The clinician, the nurse, the welcome desk
 - Right format
 - Is the layout/display appropriate? Do we need to consider patient language preferences?
 - Right channel
 - How do we organize the content given separate laboratory testing and documentation needs
 - Right time in the workflow
 - What content is needed during the overseas medical exam data extraction and during the domestic medical examination



Remember: The Computer is Never in Charge





Clinical Decision Support Standardizes Care

- Care recommendations apply routinely across the United States
 - Clinical Decision Support is an appropriate intervention
- Each organization could create its own tools
 - Lots of effort expected across organizations
 - Potential for operationalizing divergent interpretations of recommendations
 - Care would then be different based on where a patient is seen
- Organizations could use Shareable Clinical Decision Support to standardize care



Sharable Clinical Decision Support

- What is meant by Sharable Clinical Decision Support
 - Most CDS is developed at a single organization or institution others wishing to use the same process are often forced to re-invent the wheel
 - CDS that can be implemented by other organizations is considered sharable
- Numerous benefits of sharing
 - Decreases unintentional variations in care received between organizations
 - Sites that incorporate shareable CDS spend less time developing 'de novo'
 - Improvements to CDS can occur during the process of making it shareable
- Barriers to sharing exist as well
 - Each organization has its own electronic health record, own local culture, own workflows, local resources, specializations, access issues, patient populations, ...
 - Even sites that use the same electronic health record type install it differently
- How can we improve sharing?



Make it Trustworthy

- Guidance obtained from CDC on care and management of newcomer patients
- Each recommendation gets mapped to the CDS
- When guidance is updated, the new and old recommendations are compared



Refugee Health Guidelines



Immigrant and Refugee Health

Domestic Intestinal Parasite Guidelines


Presumptive Treatment and Screening for Strongyloidiasis, Infections Caused by Other Soil-Transmitted Helminths, and Schistosomiasis among Newly Arrived Refugees

Guideline Comparison Tracker	Key: Highlight = No						
Guideline	Past Guideline	Page #	Section Header, Paragraph #, Line #	New Guideline	Page #	Section Header, Paragraph #, Line #	Interpretation
Intestinal Parasite Guideline	If the eosinophil count is normal, repeat testing for eosinophilia in an asymptomatic person is not indicated.	7	Persistent eosinophilia in refugee populations; paragraph 1; lines 5-6	If the initial eosinophil count is normal, repeat testing for eosinophilia in an asymptomatic person is not indicated.	11	Persistent Eosinophilia in Refugee Populations; paragraph 1, line 1	No clinically relevant change
Intestinal Parasite Guideline	If the absolute eosinophil count is > 400 cells/mL clinical decision making should be based on the history of presumptive treatment.	7	Persistent eosinophilia in refugee populations; paragraph 1; lines 6-8	If the initial absolute eosinophil count is 450 cells/µL or greater, clinical decisionmaking should be guided by the history of presumptive treatment.	11	Persistent Eosinophilia in Refugee Populations; paragraph 1, line 1-3	Clinically relevant change

Make It Localizable

 Each organization will need to modify content to match local resources (like resettlement agencies) and organizational workflows

 Utilizing clinical terminology standards helps organizations speak the same language




CHOP Order Name	Standard	Code
CBC,Platelet With Differential	LOINC	69742-5
Hepatitis B virus panel: SAg	LOINC	58452-4
Hepatitis B Total Core AB	LOINC	22316-4
Hepatitis B Surface Antibody	LOINC	16935-9
(HIV Screening) HIV Antigen/Antibody	LOINC	56888-1
Lead (venous)	LOINC	77307-7
TB INTRADERMAL TEST	LOINC	23537-4
Quantiferon Gold	LOINC	53704-3
Urine Pregnancy Test(Office)	LOINC	2106-3
C. Trachomatis/N.Gonnorhoeae	LOINC	44806-8



Support Sharing

- Shareable CDS is NOT 'plug-and-play'
- Build guides help to orient the installation; checklists keep team organized
- While this tool was developed in Epic, guidance documents like these can help the clinical decision support be installed in any electronic health record



	Refugee Health CDS			
	Task	Task Owner	Completed	Resource Identity, Owner, or Location
	Identify Clinical Champion to serve as			
	Implementation Leader			
	Identify Impacted Clinicians and other			
	End Users			
	Identify Subject Matter Expert / Clinical			
표	Content Reviewer (can be clinical			
	champion or other clinician)			
	Identify CDS Integration Team Leader			
	Identify Data Abstractor/Analyst			
	Categorize workflow (type 1 or type 2)			
	Are there institutional documentation			
	requirements (modify templates)?			
SS	Are there institutional CDS review			
8	committee requirements?			
PROCESS	Are there institutional CDS organization			
盖	standards (modify order sets)?			
	Does your institution have the ability to			
	pull data on implementation process?			
	Plan to collect end user feedback?			
	Can implement EpicAct			
	Can modify the browser white list			
	Can determine which workflow type			
LS.	matches the organization's workflow			
SKILLS	Can check mapping of medications,			
Š	laboratory orders, and diagnosis codes			
	to local codes			
	Can check that this material matches			
	the clinical context and needs			
S	Time – Clinician Champion			
8	Time – Implementer(s)			
4	Time – Analyst 1			
ō	Time – Analyst 2			
RESOURCES	Financial Resources (if any)			
~	Patient Volume (test implementation)			
	Call to provide feedback on			
H	implementation experience			
POST	Document implementation resources			
	Monitor use of implemented resources			
	Develop a plan for updating resources			



Ways To Share Your Work


The 'you can learn to do it, too' approach


Example: The Newcomer Health Clinical Decision Support toolkit






Example: CareRef and VaxRef










Newcomer Health Clinical Decision Support



Refugee Health Decision Support

Publicly available Clinical Decision Support for Newcomer Health (Revised: May 2023)


Refugee Health Decision Support (https://cds.ahrq.gov/cdsconnect/artifact/refugee-health-decision-support)



The Share Journey

- Gather requirements: Survey of refugee health professionals (2016, N=414)
- Gather Feedback: Large scale project involving multiple healthcare organizations to define workflow (2016-2018, N=19)
- Install Local CDS: Build and testing at CHOP created a massively powerful CDS platform (2017-2018)
- Disseminate Shareable CDS: Content developed to support external builds (2019-2020)

Workgroup Consultation, Task Analysis & Guideline Review



Install at External
Sites

Sharing Begets Sharing

- Each implementation required less time and fewer revisions
- Feedback from each site lead to improvements in the build guide and the CDS toolkit
- Content which we will demonstrate today has an estimated build of <10 hours

Table 1. Implementation Across Sites

	Effort: Informaticist/ Analyst	Effort: Clinical Champions	Revision Cycles (initial build)
Origin	~20% FTE (Informaticist)	~5% FTE	5
Site 1	31 hours (Analyst)	2 hours	2
Site 2	25-30 hours (Analyst)	2 hours	1
Site 3	<10 hours (Analyst)	<1 hour	1



Clinical Decision Support Impact

- Clinicians report high satisfaction with the system
- Clinicians report that the system makes them more efficient





Adherence to Newcomer Screening Guidance

- We evaluated rates of timely newcomer screening for elevated lead, HIV, TB, anemia, eosinophilia, and hepatitis B
- We evaluated the impact of CDS on screening across Plan-Do-Study-Act (PDSA) cycles
- Very high baseline screening
 - Existing order sets did exist in the institution, but it was not automated
 - No improvement with automated tools
- Improvement in second lead testing
 - Approximately doubled timely screening rates from baseline period to the second PDSA cycle

Rate	s for each evaluated scre	eening component a	at the initial refuge	ee health evaluation	
		Screening 1	Rate (#screened/r	recommended, % s	creened) ¹
Initial Screening	Screening Recommendations	Baseline Period	PDSA Cycle 1	PDSA Cycle 2	Total
Eosinophilia	All patients	475/486 (97.74%)	114/117 (97.44%)	219/227 (96.48%)	808/830 (97.35%)
Anemia	All patients	476/486 (97.94%)	116/117 (99.15%)	219/227 (96.48%)	811/830 (97.71%)
Hepatitis B	All patients	474/486 (97.53%)	113/117 (96.58%)	219/227 (96.48%)	806/830 (97.11%)
HIV	All patients age ≥ 13y	104/107 (97.20%)	26/28 (92.86%)	53/57 (92.98%)	183/192 (95.31%)
Lead*	All patients age ≤ 16y	457/469 (97.44%)	109/112 (97.32%)	204/218 (93.58%)	770/799 (96.37%)
Tuberculosis	All patients	452/486 (93.00%)	111/117 (94.87%)	210/227 (92.51%)	773/830 (93.13%)
All screening	All patients (when recommended)	439/486 (90.33%)	107/117 (91.45%)	202/227 (88.99%)	748/830 (90.12%)

Timeframe (after initial testing) Baseline Period	PDSA Cycle 1	PDSA Cycle 2	Total
0-3 months	17 (7.30%)	6 (10.53%)	10 (15.38%)	33 (9.30%)
3-6 months ¹	37 (15.88%)	5 (8.77%)	19 (29.23%)	61 (17.18%)
6-12 months	31 (13.30%)	15 (26.32%)	7 (10.77%)	53 (14.93%)
12+ months	30 (12.88%)	2 (3.51%)	1 (1.54%)	33 (9.30%)
No follow-up testing	118 (50.64%)	29 (50.88%)	28 (43.08%)	175 (49.30%)
Total	233	57	65	355 ²

¹ Lead follow-up is recommended at 3-6 months after the initial test for all refugee patients ages ≤6 years regardless of initial screening results, older patients depending upon risk factors, and individuals with EBLL according to the CDC guidance.

² An additional 47 patients seen during PDSA cycle 2 will be due for repeat lead testing, but they were seen too recently to be included. Of these 9 had an elevated blood level at baseline.




Recap: Newcomer Health Clinical Decision Support

- Shareable clinical decision support toolkit developed at a single health system and disseminated to multiple sites
- Incorporates CDC guidance for newcomer health screening
- Informed by expert opinion for system requirements and usability
- Each successive installation was easier and took less time
- High user satisfaction after installation including more efficient care
- Initial screening rates not worse and notable improvements in timely repeat lead testing in appropriate patients



Demonstration of Newcomer Health Clinical Decision Support







CareRef: The Clinician's Assistant for Refugee Care



Our Solution: CareRef







Who is CareRef's Target Audience?

 Clinician's conducting the U.S. Domestic Medical Examination for Newly Arrived Refugees



Only 21% said it was "easy and quick" to find info within CDC guidelines
1/3 preferred an interactive tool

Many use inadequate resources



Numerous phone calls to CDC and state programs



Input

- Demographic Information
 - State of residence
 - Departure country
 - Country of birth
 - Date of Birth
 - Sex
 - Pregnancy status (if applicable)

- Overseas Screening Results
 - TB
 - Hepatitis B
 - Syphilis
 - Chlamydia
 - Gonorrhea
 - Overseas presumptive treatments received




Output

- CDC Health Alerts
- General Laboratory Testing
- Disease-Specific Laboratory Testing
 - Tuberculosis
 - Hepatitis B and C
 - Syphilis, Gonorrhea, Chlamydia
 - HIV
 - Intestinal Parasites

- History and Physical Exam
- Immunizations
- Mental Health
- Sexual and Reproductive Health
- Cancer (coming soon)
- Links to Health Profiles and Translated Materials

CareRef demo

CareRef: Clinical Assessment for Refugees (https://careref.web.health.state.mn.us/)






VaxRef: Helping Patients Translate Overseas Vaccination Records



Our Solution: VaxRef

	1		-	7			Peaxi	is ne mem	RHED	Медич	ні прот	илоказ	иния (да	rra, mpercio
Bix	Дата	4 +	. Доза		Cepix	0.1	Saramano		dozené		7			
2 221 18	MI	VIR (KI	K) DOT	153	442	H-HIN	Man	ERA.	THE			March L.	tanker i	1 1
117 Wal .	24	142 1	72	237	1 3416	MAK	Co.	0111	CNCHL	See 42	cen	12.		
Пепления о	DOTA DO	(dd.mn	a total	-	NO. L	Lotth	umber	4		. /.		,	4	
- Bix	· *-Dara	- Jud.iiiii	Доза		Cepla		Peaso	ik sa mein		Медич	ні прот	ждеказ	иний (пи	та, причи
				-			загальна		иісцева		_			
							4. 1							
				1	1.0					100		14		
Цепления г	роти крас	CHYXH .	car	116	-19					1		_	1	
Big.or	八四十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二十二	1 10	Доза	er ho A	Cepie	CH		ія ні насти		Mean	ий прот	илоказ	іння (ді	та, причи
13 18 12	4 4	un	1117	care	4 1	1	all freeze of the	03	Nichiga	your				
3	***					-		1.		-	_			1
		according to the												
Цепления г	роти гена	титу В					7 .		-		4			
2 1 1	Назва пр		Bix	Дата	:Доза	Cepis		añs Ha wen	TO BUCEOUT	1 Megge	and abou	Miloxia	anna (2	ата, причи
Baxulsauir.	118388 DP	enshery				-	320	01001	місцева	NO C			200	_
. 11	GUERLE		1-42	21.00	D7-16	201	VY#	04-004	7111	MU C	24.	N I	SUM	9_
· V.	ZONIKO	GA H.	147	45.09		5c 3	4	1120	1	-	-	_	-	
Y			19.	D2 0		23	7.	1)10	prey	1 507 .		55		+ • •
¥2	Raje		17.	D2 0			7.	100	preg	197.	7.7	- 19	<u> </u>	
нин шепле	Raje		17.	P2 0			6.	cirl 2	Hil	1997		- 14	-	
нин шепле	Raje		Bis.	Den a	J'Ilosa	Hi Cepie		CAP D	Hil	Meme				ата, приче
Bini inenne	Raje		34	In l	J'Ilosa	Hi Cepie	6. 1	ELHE /	Hit	Меди			numl	
Him thenne	Raje		34	15 10 10 10 10 10 10 10 10 10 10 10 10 10	J'Ilosa	Hi Cepie		ELHE /	Hill Missen Fast	-	Oft	en lot		pers
sim menne	Raje		34	157 16 16 16 16 16 16 16 16 16 16 16 16 16	J'Ilosa	Hi Cepie	045 4149	ELHE /	Hit	-	Oft	en lot	numl	pers
ADNT.	TOPS WAR		JAN JAN B SCC	Jan	J'Ilosa	His His	013	15.42 / 193-1	Hill	-	Oft will lett	en lot I go af ter "C	numl ter th	e ·
MAN KINE	TOPS WAR	Nie Duil	JAN JAN B. SCT	En Bis	J'Ilosa	His His	013	ELHE /	Hill	-	Oft	en lot I go af ter "C	numl ter th	pers
WAD KIT	Rafk HA HA HA Veh HA OBI ODOGU	Nie Duil	341 421 5234 B SCT	En la	04 4 04 4 05 6 1 est	Hin	013	15.42 / 193-1	Hill	15/	Oft will lett	en lot I go af ter "C	numl ter th	e .
WAD KIT	Rafk HA HA HA Veh HA OBI ODOGU	Nie Duil	34/ 44/ 8 SCC 1 34/	Style Style een	04 4 04 4 05 6 1 est	Hin	013	15.42 / 193-1	Hill	15/	Oft will lett	en lot I go af ter "C	numi ter th	e .
WAD KIT	POLA HER LANGE TO SERVICE TO SERV	Nie Nie Nie Nie Nie Nie Nie Nie Nie Nie	B SCO	En la	Post post post post post post post post p	ALCONOMICS OF THE PROPERTY OF	Cettia	Результа	Hill	15/	Oft will lett	en lot l go af ter "C"	numi ter th	Peryant
AND MATERIAL PROPERTY AND	POLA HER LANGE TO SERVICE TO SERV	Nie Nie Nie Nie Nie Nie Nie Nie Nie Nie	B SCC	En la	04 4 04 4 05 6 1 est	Addition of the second	Cettia	Результа	Hill	15/	Oft will lett	en lot l go af ter "C"	numi ter th	e Perynant
AND MATERIAL PROPERTY AND	POLA HER LANGE TO SERVICE TO SERV	Nie Nie Nie Nie Nie Nie Nie Nie Nie Nie	34 42 42 6 Sct 7 36 7 7 2	En la	Post post post post post post post post p	Addition of the second	Cettia	Penymera	Hill	Bix	Oft will lett	en lot l go af ter "C"	numi ter th	Peryman
AND MATERIAL PROPERTY AND	Pape of Pap on upodu us a	Nie Nie Nie Nie Nie Nie Nie Nie Nie Nie	341 531 1531 1531 1531 1531	En la	Post post post post post post post post p	ALCONOMICS OF THE PARTY OF THE	Cettia	Результа	Hill	Bix	Oft will lett	en lot I go af ter "C	numi ter th	Peryman



Email: kaili Test.test@gmail.com

Date of Birth: 2000-01-01

Vaccine List

vaccine_type: Measles, Mumps, Rubella (MMR)

vaccine_date: 2001-01-01

vaccine_type: Measles, Mumps, Rubella (MMR)

vaccine_date: 2005-01-01

vaccine_type: Polio (IPV)vaccine_date: 2001-03-01

vaccine_type: Polio (IPV)vaccine_date: 2001-05-01

vaccine_type: Hepatitis B
 vaccine_date: 2000-01-01

vaccine_type: Hepatitis B



Who is VaxRef's Target Audience?

Patients with vaccination records that need translation

VaxRef can be used in-clinic or outside of clinic

Translated records can be sent directly to the provider



Languages Available in VaxRef:

- English
- Ukrainian
- Russian
- Spanish
- French
- Portuguese
- More to come!





VaxRef demo

VaxRef: Immunization Record Translator (https://forms.web.health.state.mn.us/form/vaxref/)

Translate: English *	
* Asterisk (*) Indicates required field	
	nslate your vaccine records to English. Select nd complete all the information below.
Disclaimer	
· · · · · · · · · · · · · · · · · · ·	Services developed this application (VaxRef) to translate immunization ion records with the translated materials to your doctor or other health care
The application is intended for use by people who want help with translating immunization records, or commu	t to translate their immunization records, health care professionals needing nity organizations translating immunization records.
This application and its translated materials do not give care professional for advice or information about immu	e medical advice or immunization guidance. Talk to your doctor or other health unizations.
care professional for advice or information about immu Information you enter in this application, including the deleted immediately. The Minnesota Department of He this application, except for two items: (1) the US state w	
care professional for advice or information about immu Information you enter in this application, including the deleted immediately. The Minnesota Department of He this application, except for two items: (1) the US state w the translated materials. The Minnesota Department of where the application is used.	inizations. patient or user's name, date of birth and other personal information, will be alth will not have access to or store the information you provide when using there the user accessed or used the application and (2) the original language of
care professional for advice or information about immu- Information you enter in this application, including the deleted immediately. The Minnesota Department of He this application, except for two items: (1) the US state w the translated materials. The Minnesota Department of where the application is used.	inizations. patient or user's name, date of birth and other personal information, will be alth will not have access to or store the information you provide when using where the user accessed or used the application and (2) the original language of Health will use the state and language information to understand how and
care professional for advice or information about immu- Information you enter in this application, including the deleted immediately. The Minnesota Department of He this application, except for two items: (1) the US state we the translated materials. The Minnesota Department of where the application is used. If you do not wish to enter the requested information, y	unizations. patient or user's name, date of birth and other personal information, will be alth will not have access to or store the information you provide when using where the user accessed or used the application and (2) the original language of Health will use the state and language information to understand how and you cannot use the application to translate immunization records.
care professional for advice or information about immu- Information you enter in this application, including the deleted immediately. The Minnesota Department of He this application, except for two items: (1) the US state w the translated materials. The Minnesota Department of where the application is used. If you do not wish to enter the requested information, y First Name:	patient or user's name, date of birth and other personal information, will be alth will not have access to or store the information you provide when using where the user accessed or used the application and (2) the original language of Health will use the state and language information to understand how and you cannot use the application to translate immunization records. Last Name:
care professional for advice or information about immu- Information you enter in this application, including the deleted immediately. The Minnesota Department of He this application, except for two items: (1) the US state w the translated materials. The Minnesota Department of where the application is used. If you do not wish to enter the requested information, y First Name: Test	patient or user's name, date of birth and other personal information, will be alth will not have access to or store the information you provide when using where the user accessed or used the application and (2) the original language of Health will use the state and language information to understand how and you cannot use the application to translate immunization records. Last Name: Test



Patient Outreach and Quality Improvement (QI)



Identifying Patients for Outreach and QI

- Use of Clinical Decision Support leaves a trace in the Electronic Health Record (EHR)
- Organization haves the ability to pull data from the EHR
- We used a combination of markers in the chart to determine patients who were eligible for newcomer health screening
 - One of these includes utilization of the Newcomer Health CDS Toolkit
- This combined with an 'active patient' flag allows our team to target outreach and messaging to appropriate patients
- Engaged in 5 outreach and QI projects so far



1. COVID Immunization Outreach

- We recognized that COVID immunization outreach had additional barriers for newcomer patients
 - Immunization data was pulled for patients in our health system
 - We evaluated immunization uptake among newcomer patients based on primary language and looked for groups with lower than predicted rates
 - Team members reached out to cohorts of patients by preferred language to help schedule immunizations as part of the QI project



2. COVID Immunization Reconciliation

- Newcomer patients sought COVID vaccines inside and outside the medical home
- We noted that several newcomer patients who reported immunizations did not have these listed on their chart
- We identified 2 newcomer patients with separate charts for COVID vaccination and the remainder of the medical record
 - One patient had the same name in both charts
 - Second patient registered with a Americanized name when getting the COVID vaccine, other chart data and review of physical COVID helped to prove patient match
- Using the active patient list, we confirmed data providence of COVID vaccinations for these patients and merge the records
- Project demonstrated the importance of confirming legal name when providing medical care to this population to support appropriate documentation

3. Adolescent Immunization Metric (AIM-REF)

- Arriving newcomer adolescents present unique vaccination challenges
 - Delayed vaccination
 - Vaccines not accepted as valid in the United States
 - Increased rates of immunity due to prior infection
- Patient-level calculations may not correctly determine up to date status
- Existing population-level metrics may fail to identify gaps in coverage
- We developed and validated the Adolescent Immunizations Metric for REFugees (AIM-REF), for population-level immunization coverage evaluation.



AIM-REF Metric Development

Metric Population: Refugee patient, ages 12-18 years, seen with the last 3 years, arrival date more than 1 year before calculation date

Vaccination Series	Population Relevance	Handling in AIM-REF
Human Papilloma Virus, Meningococcal ACYW-135	Relevant for population, no difference from United States timing/spacing recommendations	Include in metric calculation as per standard US schedule
Tetanus, Pertussis	Relevant for population, need to account for potential of adolescent first dose for series	Include catchup schedule evaluation in metric calculation
Measles, Mumps, Rubella (MMR)	Relevant for population, handling different for MMR before age 1yr	Include valid doses as per US schedule in metric calculation
Hepatitis B	Relevant for population, low incidence of Hepatitis B carrier/disease in adolescent refugees	Include in metric calculation, account for 2-dose adolescent series (rarely used)
Poliovirus	Relevant for population, monovalent/bivalent OPV products do not provide adequate protection	Include in metric calculation if IPV or trivalent OPV (given before April 2016)
H. influenza, Pneumococcal, Rotavirus	Age at arrival in US may be after recommended age	Should not evaluate in metric
Hepatitis A, Varicella	High likelihood of natural immunity	Should not evaluate in metric
Dengue, COVID-19, Seasonal Influenza	Geographic-based recommendations, variability over time, and seasonality issues related to calculation	Should not evaluate in metric

AIM-REF Findings

Total of 326 patients across 2 health systems

- 65.8% fully vaccinated
- HPV vaccination rates lowest (a target for future QI)
- Rates lowest in younger patients, patients last seen < 2021, and US arrivals < 2019

Table 1: Vaccination Rates for 12-18 year old adolescent refugee patients seen since 2019 who arrived in the United States before November 2021, overall and by individual vaccination series, across institutions (N=326)


overall and by individual vaccination series, across institutions (N=326)									
	Up to Date								
	n	%							
All Series (AIM-REF)	214	65.8%							
Individual Vaccination Series									
1200011102		0.5.00/							
Hepatitis B	314	96.3%							
Human papilloma virus	234	71.7%							
Measles, Mumps Rubella	325	99.7%							
Meningitis ACYW-135	293	89.8%							
Poliovirus	306	93.8%							
Tetanus	281	86.2%							

±
Table 2: Vaccination rates by age, year of arrival in the United States and year of
most recent in person primary care visit caress institutions (N=325)

	Up to Date N=214		Not Up to Date N=112		
		%	n	%	p- value*
Age					<0.0001
12	25	11.7%	32	28.6%	
13	22	10.3%	32	28.6%	
14	40	18.7%	16	14.3%	
15	28	13.1%	10	8.9%	
16	35	16.4%	7	6.3%	
17	37	17.3%	9	8.0%	
18	27	12.6%	6	5.4%	
ear of Arrival in the US					0.08
Before 2019	140	65.4%	84	75.0%	
During or After 2019	74	34.6%	28	25.0%	
Year of Most Recent					
Primary Care					< 0.0001
Before 2021	48	22.4%	62	55.4%	
During or After 2021	166	77.6%	50	44.6%	

4. Newcomer Health Screening Completion

- 25 newcomer patients seen since 2020 flagged as not having timely newcomer health screening (within 30 days of DME)
- We performed a manual chart review of these patients to investigate
- Most had delayed (but completed) newcomer screening
 - Some intentionally to align with care plans
- 8 patients had documentation of prior testing scanned into the record
- Only 4 patients identified as needing outreach to complete screening





5. Targeting Clinical Areas for Improvement

- Newcomer patients with elevated lead levels seen at an increasing rates
 - Anecdotal evidence initially
 - Data from patient records used to confirm
- Investigation of patient factors found causes were multifactorial
 - Use of lead-based cosmetic products (e.g. Kohl)
 - Changes overtime in definition of elevated lead level
 - Impact of post-arrival exposure (e.g. housing and environmental factors)
- Several active interventions
 - Developed education for clinicians about newcomer lead exposure risk factors
 - Community outreach to discuss safe alternatives to lead-based cosmetic products
 - Increase timely lead follow up, scheduling visits, and identifying outreach targets
 - Including newcomer testing guidance in general lead-testing protocols in the EHR

Extending Our Work to Broader Populations

- Newcomer Clinical Decision Support toolkit adapted to create a tool applicable to other children born outside the United States
 - Need to help clinicians identify which patients may need screening
 - Evaluate screening recommendations and honed clinical decision support
 - Display existing data in the chart to guide clinician decision making
 - Eliminate content that was population specific (e.g. OME abstraction)
 - Added guidance to inform clinicians about generalized recommendations



X Remove ✓ Pend ✓ Sign

Refugee / Immigrant Orders Smart Set &

▼ Documentation

For OME data, check the CDC's Electronic Disease Notification Website (logon) For guidance on conducting a routine post-arrival medical screening of a newly arrived refugee to the U.S., see CareRef. This tool is based on the current CDC Domestic Refugee Screening Guidelines.

Overseas Medical Exam Abstraction

Overseas Medical Exam Not Available

▼ Migration History

Please go to the Social History Tab and use: .MIGRATIONHISTORY to document the migration history if available. Use Ctrl+Shift+S to return to SmartSets

▼ Laboratory Testing

CDC Domestic Medical Exam Screening Guidelines

CBC,Platelet With Differential-COMBO

Expires: 3/5/2021, Office Collect, Resulting Agency - THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Routine, Procedure Master:85025.999

HIV Antigen/Antibody-COMBO

Expires: 3/5/2021, Office Collect, Resulting Agency - THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Routine, Procedure Master:86703.002

Lead Blood

P Expected: 3/5/2020, Expires: 3/5/2021, Office Collect, Resulting Agency - THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Routine, Procedure

Ouantiferon Gold Plus

Expected: 3/5/2020, Expires: 3/5/2021, Office Collect, Resulting Agency - THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Routine, Procedure Master:86480.056

Hepatitis B Surface Antigen

Expected: 3/5/2020, Expires: 3/5/2021, Office Collect, Resulting Agency - THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Routine, Blood, Procedure Master:87340.001

✓ Hepatitis B Surface Antibody ■

Expected: 3/5/2020, Expires: 3/5/2021, Office Collect, Resulting Agency - THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Routine, Procedure Master:86706.001

Expected: 3/5/2020, Expires: 3/5/2021, Office Collect, Resulting Agency - THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Routine, Blood, Procedure Master:86704.001

Expected: 3/5/2020, Expires: 3/5/2021, Office Collect, Resulting Agency - THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Routine, Procedure Master 8/3/06/001

RPR Qualitative w/Rflx Titer-COMBO

Expected: 3/5/2020, Expires: 3/5/2021, Office Collect, Resulting Agency - THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Routine, Procedure Master:86592.002

✓ VZV IgG Serology-COMBO

Expected: 3/5/2020, Expires: 6/5/2020, Office Collect, Resulting Agency - THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Routine, Procedure Master:86787.999

✓ Hepatitis A IgG Antibody

Expected: 3/6/2020, Expires: 6/5/2020, Office Collect, Routine, Blood, Procedure Master:86790.017

✓ Hepatitis C Ab w/ Reflex-COMBO

Expected: 3/5/2020, Expires: 3/5/2021, Office Collect, Resulting Agency - THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Routine, Procedure
Macter:86803.001

G6PD Screen w/reflx to Quant

Expected: 3/5/2020, Expires: 6/5/2020, Office Collect, Routine, Procedure Master:82690.015

▼ Supplemental Pre-Visit Labs To Consider if not Already Addressed in Overseas Documentation

Strongyloides Antibody IGG-COMBO

Expected: Today Approximate, Expires: S+365, Office Collect, Routine, Consider in refugees/migrants who did not receive presumptive treatment (alternatively, US-based presumptive treatment is acceptable) Procedure Master: 86682,001

Schistosoma Antibody, IgG -O

Expected: S Approximate. Expires: S+365. Quest. Routine. Consider in refugees who did not receive presumptive treatment and patient is from schistosomiasis endemic region, see link above (alternatively, US-based presumptive treatment is acceptable). Procedure Master: 34306.001

Changes to Support Non-Refugee **Immigrant Patients**

▼ Immigrant Health Screening (Routine)

Basic screening is suggested recommended for MOST children born outside the US

- Additional screening should be based on birth country and patient age.
- See CareRef for location/age specific recommendations.

Historical relevant lab results (if present):

No results found for: "HBSAB", "HIV", "LEAD", "QFGPT", "PPD", "RPR", "EOS", "HGB", "SCHISTO"

▼ Basic Screenings Tests

- CBC.Platelet With Differential (standard for most children born outside the US)
- Expires: 1/9/2025, Office Collect, Resulting Agency CHOP UC LAB, Routine, Procedure Master.85025.999, Blood, Venous, Blood
- ✓ Hepatitis B (standard for most children born outside the US) panel
 - ✓ Hepatitis B Surface Antibody

Expires: 7/7/2024, Office Collect, Resulting Agency - CHOP UC LAB, Routine, Procedure Master:86706.001, Serum Blood

✓ Hepatitis B Surface Antigen

Expected: 1/9/2024, Expires: 1/9/2025, Office Collect, Resulting Agency - CHOP UC LAB, Routine, Procedure Master:87340.001, Serum, Blood

✓ Hepatitis B Total Core AB

Expected: 1/9/2024, Expires: 1/9/2025, Office Collect, Resulting Agency - CHOP UC LAB, Routine, Procedure Master:86704.001, Serum, Blood

- ✓ HIV Antigen/Antibody (suggested for most children born outside the US)
- Expires: 1/9/2025, Office Collect, Resulting Agency CHOP UC LAB, Routine, Procedure Master:86703.002, Plasma, **®** Blood
- ✓ Lead Blood (suggested for most children born outside the US)
 - Expires: 7/7/2024, Office Collect, Resulting Agency CHOP UC LAB, Routine, Procedure Master:83655.010, Blood, Venous, Blood
- RPR Qualitative w/Rflx Titer (suggested for most children born outside the US)
- Expires: 4/8/2024, Office Collect, Resulting Agency CHOP UC LAB, Routine, Procedure Master:86592.002, Blood, Venous, Blood
- ✓ Ouantiferon Gold
- Expected: 1/9/2024, Expires: 1/9/2025, Office Collect, Resulting Agency CHOP UC LAB, Routine, Procedure Master:86480.056, Blood, Venous, Quantiferon Collection Kit, Blood



Additional Learning Opportunities



Where Can I Learn More?







Additional Learning Opportunities



















Thank you!



Questions?



Center of Excellence Reminders!

Subscribe to Center of Excellence in Newcomer Health Updates

(https://public.govdelivery.com/accounts/ MNMDH/subscriber/new?topic_id=MNM DH_463) for training announcements and other guidance and resources.

Upcoming trainings at

Center of Excellence in Newcomer Health:
Webinars
(www.health.state.mn.us/communities/rih/about/coe.html#webinar)

NEWCOMER HEALTH



This ECHO series increases medical providers' knowledge of the resettlement and health issues of newcomers, including refugee, immigrant and migrant (RIM) populations.

It reviews resettlement pathways, evidence-based screening recommendations, and more common diagnoses and treatment approaches for pediatric and adult populations.

Sessions include brief didactic presentations by immigrant health experts and discussion of participant-submitted cases. Participants are highly encouraged to submit de-identified patient cases for group discussion and expert consultation.





ECISTED HEDE



ONGOING MONTHLY VIRTUAL SESSIONS

Last Tuesday of the month 8:00 AM PT \mid 9:00 AM MT \mid 10:00 AM CT \mid 11:00 AM ET

REGISTER TODAY!

echocolorado.org/echo/newcomer-health/

UPCOMING SESSIONS

JANUARY 30

Asylum Seekers and Shelters

FEBRUARY 27

Clinical Considerations for Latin American Newcomers

MARCH 26

Trauma Informed/Preventative Care for Newcomer
Women



2/8/2024

Thank You! Please remember to complete your evaluation

